ANCA-associated vasculitis: Diagnostic and therapeutic strategy

Allergology International

Volumn 56, Issue 2, 2007, Pages 87-96

  Ozaki, Shoichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allergic granulomatous angiitis; Anti neutrophil cytoplasmic antibody; Cyclophosphamide; Microscopic polyangiitis; Myeloperoxidase; Proteinase 3; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPYRIDAMOLE; ETANERCEPT; ETOPOSIDE; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; CANCER; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; EVIDENCE BASED MEDICINE; GEOGRAPHY; GLOMERULONEPHRITIS; HUMAN; LEUKOCYTE ACTIVATION; MEDICAL ASSESSMENT; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

EID: 34250836917     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.R-07-141     Document Type: Review

References (41)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
2. Jennette JC, Falk RJ. Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? Clin. Exp. Immunol. 1995;101(Suppl 1):18-22.
3. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 1988;318: 1651-1657.
4. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-429.
5. Jennette JC, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol. Dial. Transplant 1998;13(Suppl 1):16-20.
6. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 2002;110:955-963.
7. Nakabayashi K, Hashimoto H. Microscopic polyangiitis. In: Hashimoto H (ed). Clinical Manual for Vasculitis. Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan, 2002;24-26.
8. Yoshida M. Wegener's granulomatosis. In: Hashimoto H (ed). Clinical Manual for Vasculitis. Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan, 2002;30-34.
9. Tsusaka N. Allergic granulomatous angiitis. In: Hashimoto H (ed). Clinical Manual for Vasculitis. Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan, 2002;27-29.
10. Jennette JC, Falk RJ. Small-vessel vasculitis. N. Engl. J. Med. 1997;337:1512-1523.
11. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am. J. Pathol. 1951;27:277-301.
12. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994;87:671-678.
13. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-380.
14. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 1992;116:488-498.
15. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003;349:36-44.
16. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 2005;352: 351-361.
17. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469.
18. Stone JH, Holbrook JT, Marriott MA et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006;54:1608-1618.
19. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J. Am. Soc. Nephrol. 2006;17:2264-2274.
20. Appel GB, Kaplan AA, Stone JH. Initial and maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis. UpToDate Online, version 14.3
21. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 1996;335:16-20.
22. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant 2005;20:2725-2732.
23. Koukoulaki M, Jayne DR. Mycophenolate mofetil in antineutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron. Clin. Pract. 2006;102:c100-107.
24. Allen NB, Caldwell DS, Rice JR, McCallum RM. Cyclosporin A therapy for Wegener's granulomatosis. Adv. Exp. Med. Biol. 1993;336:473-476.
25. Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol. Dial. Transplant 1998;13: 2074-2076.
26. Ozaki S, Nakabayashi K, Tomino Y, Koyama T. A prospective, open-labeled, and multi-center trial of standard protocols for MPO-ANCA-associated vasculitis by Japanese study group for MPO-ANCA-associated vasculitis (JMAAV). Annual report 2005 of the Research Group for Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan. 2006;199-323.
27. Rose BD, Appel GB, Stone JH. Alternative agents in the treatment of Wegener's granulomatosis and microscopic polyangiitis. UpToDate Online, version 14.3
28. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004;15:717-721.
29. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-268.
30. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 2006; 65:853-858.
31. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341: 1620-1622.
32. Schmitt WH, Hagen EC, Neumann I, Nowack R. Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65: 1440-1448.
33. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm 2000;93:433-439.
34. Muso E, Ito-Ihara T, Ono T et al. Intravenous immunoglobulin (TVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn. J. Infect. Dis. 2004;57:S17-18.
35. Morton SJ, Lanyon PC, Powell RJ. Etoposide in Wegener's granulomatosis. Rheumatology (Oxford) 2000; 39:810-811.
36. Birck R, Warnatz K, Lorenz HM et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 2003;14:440-447.
37. Schmitt WH, Birck R, Heinzel PA et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin:an open study in seven patients. Nephrol. Dial. Transplant 2005;20:1083-1092.
38. Benenson E, Fries JW, Heilig B, Pollok M, Rubbert A. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin. Rheumatol. 2005;24:251-257.
39. Eagleton LE, Rosher RB, Hawe A, Bilinsky RT. Radiation therapy and mechanical dilation of endobronchial obstruction secondary to Wegener's granulomatosis. Chest 1979;76:609-610.
40. Neviani CB, Carvalho Hde A, Hossamu C, Aisen S, Nadalin W. Radiation therapy as an option for upper airway obstruction due to Wegener's granulomatosis. Oto laryngol. Head Neck Surg. 2002;126:195-196.
41. Kotter I, Daikeler T, Amberger C, Tyndall A, Kanz L. Autologous stem cell transplantation of treatment-resistant systemic vasculitis - a single center experience and review of the literature. Clin. Nephrol. 2005;64:485-489.